Last reviewed · How we verify
NCT01579968
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery
trial testing eptacog alfa (activated) in Congenital Bleeding Disorder in 86 participants. Completed in 9 March 2010.
9 March 2010
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 86 |
| Start date | 10 March 1999 |
| Primary completion | 9 March 2010 |
| Estimated completion | 9 March 2010 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- eptacog alfa (activated) (EPTACOG ALFA (ACTIVATED)) — full drug profile →
Conditions studied
- Congenital Bleeding Disorder — all drugs for Congenital Bleeding Disorder →
- Haemophilia A With Inhibitors — all drugs for Haemophilia A With Inhibitors →
- Haemophilia B With Inhibitors — all drugs for Haemophilia B With Inhibitors →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
Eligibility, any sex, with Congenital Bleeding Disorder or Haemophilia A With Inhibitors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is conducted in Japan. The aim of this non-interventional study is to investigate the safety and effectiveness of treatment with eptacog alpha (NovoSeven®) when undergoing surgery under normal clinical practice conditions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01579968
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of eptacog alfa (activated)
Trials testing the same drug.
- NCT01876745 — A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan · completed
- NCT01586936 — Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With I · completed
- NCT01579955 — Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical P · completed
Other recruiting trials for Congenital Bleeding Disorder
Currently open trials in the same condition.
- NCT06574984 — Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients · recruiting
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01579968 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 24 February 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01579968.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing